Target intelligence / Profile preview

Protein lin-52 homolog (LIN52)

Target
LIN52
Molecular classification
Transcriptional regulatory complex component, Other
01

Overview

Protein lin-52 homolog (LIN52) is a small protein subunit of the MuvB core complex, which is central to the assembly and function of cell cycle-regulatory transcriptional complexes: DREAM (quiescent state gene repression) and MMB/FOXM1-MuvB (mitotic gene activation)[1][2][3][4][5]. LIN52 is responsible for recruiting pocket proteins p107/p130 and B-MYB, controlling dynamic transitions between cell cycle phases. Phosphorylation by DYRK1A at Ser28 on LIN52 triggers DREAM complex formation by enabling specific binding to p107/p130, thus repressing cell cycle genes during cell quiescence[1][3]. When not phosphorylated, LIN52 helps form the MMB complex with B-MYB that activates mitotic gene transcription[1][2]. LIN52 itself acts only within these multi-protein complexes, and there are no known drugs targeting it directly. Dysfunction of the MuvB/DREAM complex, including LIN52, is implicated in cancer through loss of cell cycle checkpoint control and abnormal cell proliferation[1][3][5].

Other names
LIN52Protein lin-52 homologC14orf46c14_5549lin-52 homolog
02

Mechanism of action

Not applicable directly; no drugs act on LIN52 itself. Indirect mechanism: Kinase inhibitors (e.g., DYRK1A inhibitors) may modulate DREAM complex assembly by affecting LIN52 phosphorylation[3].

03

Biological functions

Cell cycle regulation (through DREAM and MMB complexes)Transcriptional repression (in quiescence via DREAM)Transcriptional activation (in S/G2/M phase via MMB/FOXM1 complexes)
04

Disease associations

Cancer (aberrations in DREAM/MuvB complex protein function and regulation are implicated in cancer progression and cell cycle dysregulation)
05

Safety considerations

No direct therapeutic interventions targeting LIN52 are reported, thus no safety concerns specific to interventions at LIN52.
06

Interacting drugs

None reported.
07

Biomarkers

None specific to LIN52 currently used in clinical settings. Expression or phosphorylation status of MuvB complex components may correlate with cell cycle states or cancer, but LIN52 itself is not a standard biomarker[1][3][5].

Beyond the preview

Go deeper on Protein lin-52 homolog (LIN52).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein lin-52 homolog (LIN52).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call